Cerus (CERS) Stock: Buy, Sell, or Hold?
CERS - Cerus Corp
$2.49
0.03 (1.22%)
â˛
5d:
-3.11%
30d:
-8.12%
90d:
-3.86%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CERS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CERS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CERS is currently trading at $2.49, which is considered slightly low relative to its 30-day fair value range of $2.40 to $2.81. From a valuation perspective, the stock is trading at a discount (Forward PE: -498.0) compared to its historical average (76.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CERS is in a downtrend. The price is currently testing key support at $2.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CERS scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.12 (+105.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CERS is in a downtrend. The price is currently testing key support at $2.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CERS scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.12 (+105.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.40 -
$2.81
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 105.8% below Wall St target ($5.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.40 -
$2.81
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.45
Resistance Level
$2.73
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-498.00
Wall Street Target
$5.13
(+105.8%)
Revenue Growth (YoY)
9.5%
Profit Margin
-3.1%
PE vs Historical
-498.0 vs 76.8
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 1:24 AM ET
Data refreshes hourly during market hours. Next update: 2:24 AM
Data refreshes hourly during market hours. Next update: 2:24 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
